CCR2 Genotype and Disease Progression in a Treated Population of HIV Type 1-Infected Women | Zendy

Sean Philpott | Zendy; Harold Burger | Zendy; Patrick M. Tarwater | Zendy; MingChi Lu | Zendy; Stephen J. Gange | Zendy; K. Anastos | Zendy; Mardge H. Cohen | Zendy; Ruth M. Greenblatt | Zendy; Andrea Kovacs | Zendy; Howard Minkoff | Zendy; Mary H. Young | Zendy; P Miotti | Zendy; Michelle Dupuis | Zendy; Barbara Weiser | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CCR2 Genotype and Disease Progression in a Treated Population of HIV Type 1-Infected Women

Author(s) -

Sean Philpott,

Harold Burger,

Patrick M. Tarwater,

MingChi Lu,

Stephen J. Gange,

K. Anastos,

Mardge H. Cohen,

Ruth M. Greenblatt,

Andrea Kovacs,

Howard Minkoff,

Mary H. Young,

P Miotti,

Michelle Dupuis,

Barbara Weiser

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/423386

Subject(s) - medicine , genotype , disease , population , immunology , human immunodeficiency virus (hiv) , virology , genetics , gene , environmental health , biology

Both antiretroviral therapy and the human coreceptor polymorphism CCR2-V64I slow progression of human immunodeficiency virus type 1 (HIV-1) disease. To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort. We studied 2047 HIV-1-infected women, most of whom initiated treatment during the study. No association was seen between CCR2 genotype and either disease progression or therapeutic response, suggesting that the benefits of treatment most likely overshadow the salutary effects of the V64I polymorphism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research